ARTICLE | Finance
Dampening expectations
August 16, 1993 7:00 AM UTC
Noteworthy
Regeneron Pharmaceuticals Inc. stock responded negatively to the company's disclosure last week that there was no significant difference between drug and placebo in its Phase II trial of ciliary neurotrophic factor to treat amyotrophic lateral sclerosis. But the small size of the trial makes it impossible to draw many conclusions about CNTF's efficacy...